New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareGHK-Cu vs Cardiogen

GHK-Cu vs Cardiogen

Side-by-side comparison of key properties, dosing, and research.

Skin & CosmeticRecovery & RepairAnti-Aging & Longevity
GHK-Cu
Anti-Aging & Longevity
Cardiogen
Summary
GHK-Cu is a naturally occurring copper complex that declines with age. It is one of the most studied anti-aging peptides, known for powerful skin rejuvenation, wound healing, and tissue remodeling effects.
Cardiogen is a tetrapeptide bioregulator (Ala-Glu-Asp-Arg) developed by Professor Vladimir Khavinson. It is a tissue-specific bioregulator for the heart and myocardium, designed to normalize cardiomyocyte function and support cardiac tissue regeneration. Research has demonstrated cardioprotective effects, improved cardiac rhythm, and benefits in recovery from ischemic injury.
Half-Life
2–4 hours
Short (minutes); gene-regulatory effects persist longer
Admin Route
SubQ, Topical
SubQ, Oral
Research
Typical Dose
1–3 mg
10 mg per day
Frequency
3–5 times per week
Daily for 10–30 days
Key Benefits
  • Reduces wrinkles and fine lines
  • Improves skin firmness and elasticity
  • Accelerates wound healing
  • Reduces inflammation and oxidative damage
  • Promotes hair growth and thickness
  • Supports collagen and elastin production
  • May improve overall skin health and appearance
  • Resets aged fibroblast behavior
  • Anti-fibrotic — reduces scar tissue formation
  • Cardioprotective effects on myocardial tissue
  • Normalization of cardiomyocyte protein synthesis
  • May improve cardiac rhythm and conduction
  • Support for recovery from ischemic cardiac events
  • Anti-aging effects on heart tissue
  • Potential reduction in cardiac fibrosis
  • Often combined with Epithalon for comprehensive cardiovascular longevity support
Side Effects
  • Temporary blue-green discoloration at injection site (from copper — harmless)
  • Post-injection sting (brief)
  • Skin irritation with topical use (rare)
  • Generally well tolerated in available research
  • Mild injection site reactions
  • No significant adverse cardiovascular events reported at standard doses
Stacks With